Xintela AB
Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indicati… Read more
Xintela AB - Asset Resilience Ratio
Xintela AB (XINT) has an Asset Resilience Ratio of 37.25% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Xintela AB's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Xintela AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr3.38 Million | 37.25% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr3.38 Million | 37.25% |
Asset Resilience Insights
- Very High Liquidity: Xintela AB maintains exceptional liquid asset reserves at 37.25% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Xintela AB Industry Peers by Asset Resilience Ratio
Compare Xintela AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Xintela AB (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Xintela AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 67.26% | Skr16.68 Million | Skr24.80 Million | +24.81pp |
| 2023-12-31 | 42.45% | Skr7.81 Million | Skr18.39 Million | +8.42pp |
| 2022-12-31 | 34.03% | Skr8.34 Million | Skr24.52 Million | -14.38pp |
| 2021-12-31 | 48.41% | Skr11.98 Million | Skr24.74 Million | -20.85pp |
| 2020-12-31 | 69.26% | Skr33.60 Million | Skr48.51 Million | +66.85pp |
| 2019-12-31 | 2.41% | Skr412.00K | Skr17.09 Million | -60.74pp |
| 2018-12-31 | 63.16% | Skr31.40 Million | Skr49.71 Million | -13.49pp |
| 2017-12-31 | 76.65% | Skr21.91 Million | Skr28.59 Million | -2.93pp |
| 2016-12-31 | 79.58% | Skr18.98 Million | Skr23.85 Million | -- |